A Study of SDI-118 in Participants in Remission From Depression

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE1

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-16

Study Completion Date

2022-03-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multi-center, double-blind, randomized, placebo-controlled study to determine the safety, tolerability, and pharmacodynamics of SDI-118 in a once daily (QD) dosing regimen on male and female study participants reporting with cogntive decline and who in remission from depression.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Safety, Efficacy and Tolerability Study of SEP-225289

NCT00584974

Depressive Disorder, Major

COMPLETED PHASE2

A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine

NCT06280235

Depressive Disorder, Major

COMPLETED PHASE2

Study of Desvenlafaxine in Treating Major Depressive Disorder.

NCT04364997

Major Depressive Disorder

COMPLETED PHASE3

A Study of Sustained-Release Desvenlafaxine Hydrochloride for the Treatment of Major Depressive Disorder

NCT01977378

Major Depressive Disorder

UNKNOWN PHASE2/PHASE3

A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder

NCT03000530

Major Depression

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression in Remission

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind Primary Purpose: Treatment

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SDI-118 low dose

SDI-118 (low dose) orally once daily (QD) for 17±1 day.

Group Type EXPERIMENTAL

SDI-118

Intervention Type DRUG

SDI-118 is presented as low dose, and high dose capsules.

SDI-118 high dose

SDI-118 (high dose) orally once daily (QD) for 17±1 day.

Group Type EXPERIMENTAL

SDI-118

Intervention Type DRUG

SDI-118 is presented as low dose, and high dose capsules.

Placebo

Placebo orally once daily (QD) for 17±1 day.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

The Matching Placebo for SDI-118 is mannitol in capsules.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SDI-118

SDI-118 is presented as low dose, and high dose capsules.

Intervention Type DRUG

Placebo

The Matching Placebo for SDI-118 is mannitol in capsules.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female participants between 25 and 55 years of age (inclusive) at screening.
* Are remitted from depression.
* Have received prescribed treatment with an antidepressant or a recognised psychotherapy for depression (e.g. cognitive behaviour therapy) for a previous MDE
* Report present subjective cognitive impairment (such as difficulty concentrating, slow thinking, and difficulty in learning new things or remembering things).
* Have not been treated with antidepressants or received other psychotherapy for depression for at least six weeks prior to Screening Visit 1.
* Otherwise healthy with no clinically significant abnormalities as determined by medical history, physical examination, blood chemistry assessments, haematologic assessments, and urinalysis, measurement of vital signs, and Electrocardiogram (ECG).
* Negative serology test for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibodies at screening.
* Have a body mass index (BMI) of 18 to 36 inclusive.
* Agree not to use herbal medications (including herbal tea, St. John's Wort), within 14 days prior to study agent administration through to the final follow-up visit.
* Participants must be able and willing to give written, informed consent, indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
* The participant, in the opinion of the investigator, is willing and able to adhere to the study visit schedule and other requirements, prohibitions and restrictions of the study.

Exclusion Criteria

* They are left-handed.
* Have immediate recall of greater than 22 words from the International Shopping List Test (ISLT) and have delayed recall of greater than 8 words from the ISLT 15 mins after the presentation of the word list.
* Positive urine drug screen or alcohol breath test at screening or assessment visits.
* History or presence of significant neurological or psychiatric conditions except those related to MDD.
* Any suicidal ideation of type 4 or 5 in the Columbia Suicide Severity Rating Scale (C-SSRS) in the past 3 months prior to screening or at screening or baseline visit.
* Has a known clinically relevant structural brain abnormality as determined by e.g. previous MRI, or, persistent MRI imaging artefact which is judged to produce extensive imaging distortions.
* Has a disease or takes medication that could, in the investigator's and/or sponsor's opinion, interfere with the assessments of safety, tolerability, or efficacy, or interfere with the conduct or interpretation of the study.

Minimum Eligible Age

25 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes